• Explore /
  • Poster
  • / A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with <em>KRAS</em> mutation: JUNIPER.

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

Abstract Poster

Authors

Jonathan Goldman

Jonathan Wade Goldman

UCLA Medical Center, Los Angeles, CA

Jonathan Wade Goldman , Julien Mazieres , Fabrice Barlesi , Marianna Koczywas , Konstantin H. Dragnev , Tuncay Göksel , Alexis B. Cortot , Nicolas Girard , Claas Wesseler , Helge Bischoff , Ernest Nadal , Keunchil Park , Shun Lu , Alvaro Taus , Manuel Cobo , Karla Hurt , Alan Chiang , Anwar Hossain , William J. John , Luis G. Paz-Ares

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02152631

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9025)

DOI

10.1200/JCO.2018.36.15_suppl.9025

Abstract #

9025

Poster Bd #

348

Abstract Disclosures

Similar Posters

First Author: Giorgio V. Scagliotti

First Author: Sukhmani Kaur Padda

First Author: Sara A. Hurvitz

First Author: Matthew Raymond Smith